http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
세탁기용 VCM 강판 성형시 PET 코팅층 찢김 저감방법
손영기(Young-Ki Son),이찬주(Chan-Joo Lee),변상덕(Sang-Doek Byeon),김명덕(Myong-Dok Kim),김병민(Byung-Min Kim) 대한기계학회 2011 大韓機械學會論文集A Vol.35 No.9
VCM 강판은 용융아연도금강판 위에 PET/PVC 코팅하여 가전제품의 외판 소재로 사용되고 있다. 본 연구에서는 VCM 강판의 프레스 성형 중 발생하는 PET 코팅층의 찢김을 저감하기 위해 프레스 성형공정변수를 재설계하였다. 프레스 공정변수들이 PET 코팅층의 찢김에 미치는 영향을 분석하기 위해 유한요소해석을 수행하였다. PET 코팅의 찢김 현상은 드로잉 성형시 제품의 코너부 소재두께의 증가로 인해 금형과 소재 사이의 과도한 마찰에 의해 발생한다. 이를 해결하기 위해 블랭크 형상의 변경을 통해 드로잉 성형시 코너부의 소재두께 증가를 저감하였으며, 트리밍 공정시 플랜지부의 과도한 두께 증가부분을 제거하여 플랜지 성형시 소재두께가 금형간극 이하로 분포하도록 하였다. 또한 성형실험과 유한요소해석을 통해 재설계된 공정변수들을 검증하였다. 이를 통해 PET 코팅의 찢김이 없는 양호한 최종제품의 성형이 가능함을 확인하였다. A VCM sheet is a metal sheet on which PET/PVC is coated for outer panels of home appliances. The purpose of this study is to obtain methods for suppressing PET tearing that occurs during the press forming of the VCM sheet. In order to identity the factors that minimize PET tearing, an FE analysis was performed. The occurrence of PET tearing cannot be predicted using the conventional forming limit diagram. PET is torn by friction between a die and sheet, which is caused by the thickening of material at a die corner. To reduce the thickening of material, the blank shape was re-designed and the thickened material at a flange was removed by a trimming process. The results of the FE-analysis involving modified process parameters showed that the thickness of the product at a die corner is distributed within the clearance of drawing and flangeforming process. A forming experiment was conducted to verify the proposed process parameters. A good final product was obtained without PET tearing of the VCM sheet.
Chae, Sun Young,Kim, Sung-Bae,Ahn, Sei Hyun,Kim, Hye Ok,Yoon, Dok Hyun,Ahn, Jin-Hee,Jung, Kyung Hae,Han, Sangwon,Oh, Seung Jun,Lee, Sang Ju,Kim, Hee Jeong,Son, Byung Ho,Gong, Gyungyub,Lee, Hyo Sang,Mo Society of Nuclear Medicine 2017 The Journal of nuclear medicine Vol.58 No.4
<P>The aim of this study was to explore the ability of F-18-fluoroestradiol (F-18-FES) PET/CT imaging to predict pathologic response to neo-adjuvant therapy in postmenopausal women with estrogen receptor (ER)-rich breast cancer. Methods: This was a prospective, single center study conducted as a substudy of the neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer (NEOCENT) trial. Patients with ER -rich breast cancer were randomized to neoadjuvant chemotherapy (NC) or neoadjuvant endocrine therapy (NET). The baseline SUVmax of F-18-FES PET/CT was measured. The pathologic response was assessed by the Miller-Payne system as nonresponse (grades 1 and 2) and response (grades 3-5). Results: Twenty-six patients were enrolled, with pathologic response achieved in 25 (NC, 12; NET, 13). Two patients achieved pathologic complete response after NC, but the remaining 23 patients had residual disease after NC or NET. Eight of 12 patients responded to NC, and 4 of 13 to NET; the difference was marginally significant (P = 0.07). In the NC group, the 2 patients with F-18-FES-negative tumors and none of the 10 patients with F-18-FES-avid tumors achieved pathologic complete response (P = 0.02). No difference in the SUVmax between responders and nonresponders was observed in either group. However, 5 of 7 NC patients with a baseline SUVmax of less than 7.3 achieved pathologic response, whereas none of the 5 NET patients with an SUVmax of less than 7.3 were responders (P = 0.03). The SUVmax values of the NC group were negatively correlated with percentage reduction of tumor cellularity (r = -0.63, P = 0.03), whereas those of the NET group showed positive correlation (r = 0.62, P = 0.02). During the median follow-up of 74 mo (range, 44-85 mo), recurrence occurred in only 4 NET patients. In patients with an SUVmax of less than 7.3, recurrence occurred in none of the 8 NC patients and 2 of the 5 NET patients (P = 0.13). Conclusion: Postmenopausal women who are ER-positive, but F-18-FES-negative, may benefit from NC rather than NET. F-18-FES PET/CT has the potential to predict response to neoadjuvant therapy in postmenopausal women with ER -rich breast cancer.</P>